Cover Image
Market Research Report

Pancreatic Cancer - Global Market Outlook (2017-2026)

Published by Stratistics Market Research Consulting Product code 907703
Published Content info 183 Pages
Delivery time: 2-3 business days
Price
Back to Top
Pancreatic Cancer - Global Market Outlook (2017-2026)
Published: August 19, 2019 Content info: 183 Pages
Description

According to Stratistics MRC, the Global Pancreatic Cancer market is accounted for $1,904.20 million in 2017 and is expected to reach $4,728.19 million by 2026 growing at a CAGR of 10.6% during the forecast period. Advancement of technology in therapeutic devices and expanding prevalence of cancer growth are the factors driving the market. However, accessibility of costly treatment and poor repayment strategies in the emerging regions of the world are some of the factors which may hamper the market growth during the forecast period.

Pancreatic Cancer is a type of cancer that starts in the pancreas. It is a highly lethal disease, for which mortality closely parallels incidence. Most patients with Pancreatic Cancer remain asymptomatic until the disease reaches an advanced stage. There is no standard programme for screening patients at high risk of Pancreatic Cancer. Most Pancreatic Cancers arise from microscopic non-invasive epithelial proliferations within the pancreatic ducts, referred to as pancreatic intraepithelial neoplasias.

Based on the treatment, the biologic therapy has a huge demand due to expanding number of novel upcoming immunotherapies as well as focused cell therapy that treats the cancer with no extreme symptoms and has more number of helpful advantages over the conventional chemotherapies.

By geography, Asia Pacific is growing lucratively during the forecast period owing to the nearness of quickly creating medicinal services innovation, high patient population, and high social insurance use. Additionally, expanding interest for new treatment strategies in nations like India and South Korea is probably going to develop as the quickest developing business sector over the globe.

Some of the key players in the Pancreatic Cancer market include Novartis Ag, Eli Lily and Company, F. Hoffmann-La Roche AG, Pharmacyte Biotech, Inc, Clovis Oncology, Celgene Corporation, Teva Pharmaceutical Industries Ltd., Amgen, Inc., Pfizer, Inc. and Merck & Co., Inc.

Treatments Covered:

  • Biologic Therapy
  • Hormone Therapy
  • Chemotherapy
  • Targeted Therapy
  • Surgery
  • Radiation Therapy
  • Other Treatments

Types Covered:

  • Exocrine Pancreas Cancer
  • Endocrine Pancreas Cancer

End Users Covered:

  • Research Institute
  • Hospitals & Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country level segments
  • Strategic recommendations for the new entrants
  • Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic analysis: Drivers and Constraints, Product/Technology Analysis, Porter's five forces analysis, SWOT analysis etc.
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the clients interest (Note: Depends of feasibility check)
  • Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances.

Table of Contents

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Futuristic Market Scenario

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Pancreatic Cancer Market, By Treatment

  • 5.1 Introduction
  • 5.2 Biologic Therapy
  • 5.3 Hormone Therapy
  • 5.4 Chemotherapy
  • 5.5 Targeted Therapy
  • 5.6 Surgery
  • 5.7 Radiation Therapy
  • 5.8 Other Treatments

6 Global Pancreatic Cancer Market, By Type

  • 6.1 Introduction
  • 6.2 Exocrine Pancreas Cancer
  • 6.3 Endocrine Pancreas Cancer

7 Global Pancreatic Cancer Market, By End User

  • 7.1 Introduction
  • 7.2 Research Institute
  • 7.3 Hospitals & Clinics
  • 7.4 Other End Users

8 Global Pancreatic Cancer Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Novartis Ag
  • 10.2 Eli Lily and Company
  • 10.3 F. Hoffmann-La Roche AG
  • 10.4 Pharmacyte Biotech, Inc
  • 10.5 Clovis Oncology
  • 10.6 Celgene Corporation
  • 10.7 Teva Pharmaceutical Industries Ltd.
  • 10.8 Amgen, Inc.
  • 10.9 Pfizer, Inc.
  • 10.10 Merck & Co., Inc.

List of Tables

  • 1 Global Pancreatic Cancer Market Outlook, By Region (2016-2026) (US $MN)
  • 2 Global Pancreatic Cancer Market Outlook, By Treatment (2016-2026) (US $MN)
  • 3 Global Pancreatic Cancer Market Outlook, By Biologic Therapy (2016-2026) (US $MN)
  • 4 Global Pancreatic Cancer Market Outlook, By Hormone Therapy (2016-2026) (US $MN)
  • 5 Global Pancreatic Cancer Market Outlook, By Chemotherapy (2016-2026) (US $MN)
  • 6 Global Pancreatic Cancer Market Outlook, By Targeted Therapy (2016-2026) (US $MN)
  • 7 Global Pancreatic Cancer Market Outlook, By Surgery (2016-2026) (US $MN)
  • 8 Global Pancreatic Cancer Market Outlook, By Radiation Therapy (2016-2026) (US $MN)
  • 9 Global Pancreatic Cancer Market Outlook, By Other Treatments (2016-2026) (US $MN)
  • 10 Global Pancreatic Cancer Market Outlook, By Type (2016-2026) (US $MN)
  • 11 Global Pancreatic Cancer Market Outlook, By Exocrine Pancreas Cancer (2016-2026) (US $MN)
  • 12 Global Pancreatic Cancer Market Outlook, By Endocrine Pancreas Cancer (2016-2026) (US $MN)
  • 13 Global Pancreatic Cancer Market Outlook, By End User (2016-2026) (US $MN)
  • 14 Global Pancreatic Cancer Market Outlook, By Research Institute (2016-2026) (US $MN)
  • 15 Global Pancreatic Cancer Market Outlook, By Hospitals & Clinics (2016-2026) (US $MN)
  • 16 Global Pancreatic Cancer Market Outlook, By Other End Users (2016-2026) (US $MN)
  • 17 North America Pancreatic Cancer Market Outlook, By Country (2016-2026) (US $MN)
  • 18 North America Pancreatic Cancer Market Outlook, By Treatment (2016-2026) (US $MN)
  • 19 North America Pancreatic Cancer Market Outlook, By Biologic Therapy (2016-2026) (US $MN)
  • 20 North America Pancreatic Cancer Market Outlook, By Hormone Therapy (2016-2026) (US $MN)
  • 21 North America Pancreatic Cancer Market Outlook, By Chemotherapy (2016-2026) (US $MN)
  • 22 North America Pancreatic Cancer Market Outlook, By Targeted Therapy (2016-2026) (US $MN)
  • 23 North America Pancreatic Cancer Market Outlook, By Surgery (2016-2026) (US $MN)
  • 24 North America Pancreatic Cancer Market Outlook, By Radiation Therapy (2016-2026) (US $MN)
  • 25 North America Pancreatic Cancer Market Outlook, By Other Treatments (2016-2026) (US $MN)
  • 26 North America Pancreatic Cancer Market Outlook, By Type (2016-2026) (US $MN)
  • 27 North America Pancreatic Cancer Market Outlook, By Exocrine Pancreas Cancer (2016-2026) (US $MN)
  • 28 North America Pancreatic Cancer Market Outlook, By Endocrine Pancreas Cancer (2016-2026) (US $MN)
  • 29 North America Pancreatic Cancer Market Outlook, By End User (2016-2026) (US $MN)
  • 30 North America Pancreatic Cancer Market Outlook, By Research Institute (2016-2026) (US $MN)
  • 31 North America Pancreatic Cancer Market Outlook, By Hospitals & Clinics (2016-2026) (US $MN)
  • 32 North America Pancreatic Cancer Market Outlook, By Other End Users (2016-2026) (US $MN)
  • 33 Europe Pancreatic Cancer Market Outlook, By Country (2016-2026) (US $MN)
  • 34 Europe Pancreatic Cancer Market Outlook, By Treatment (2016-2026) (US $MN)
  • 35 Europe Pancreatic Cancer Market Outlook, By Biologic Therapy (2016-2026) (US $MN)
  • 36 Europe Pancreatic Cancer Market Outlook, By Hormone Therapy (2016-2026) (US $MN)
  • 37 Europe Pancreatic Cancer Market Outlook, By Chemotherapy (2016-2026) (US $MN)
  • 38 Europe Pancreatic Cancer Market Outlook, By Targeted Therapy (2016-2026) (US $MN)
  • 39 Europe Pancreatic Cancer Market Outlook, By Surgery (2016-2026) (US $MN)
  • 40 Europe Pancreatic Cancer Market Outlook, By Radiation Therapy (2016-2026) (US $MN)
  • 41 Europe Pancreatic Cancer Market Outlook, By Other Treatments (2016-2026) (US $MN)
  • 42 Europe Pancreatic Cancer Market Outlook, By Type (2016-2026) (US $MN)
  • 43 Europe Pancreatic Cancer Market Outlook, By Exocrine Pancreas Cancer (2016-2026) (US $MN)
  • 44 Europe Pancreatic Cancer Market Outlook, By Endocrine Pancreas Cancer (2016-2026) (US $MN)
  • 45 Europe Pancreatic Cancer Market Outlook, By End User (2016-2026) (US $MN)
  • 46 Europe Pancreatic Cancer Market Outlook, By Research Institute (2016-2026) (US $MN)
  • 47 Europe Pancreatic Cancer Market Outlook, By Hospitals & Clinics (2016-2026) (US $MN)
  • 48 Europe Pancreatic Cancer Market Outlook, By Other End Users (2016-2026) (US $MN)
  • 49 Asia Pacifc Pancreatic Cancer Market Outlook, By Country (2016-2026) (US $MN)
  • 50 Asia Pacifc Pancreatic Cancer Market Outlook, By Treatment (2016-2026) (US $MN)
  • 51 Asia Pacifc Pancreatic Cancer Market Outlook, By Biologic Therapy (2016-2026) (US $MN)
  • 52 Asia Pacifc Pancreatic Cancer Market Outlook, By Hormone Therapy (2016-2026) (US $MN)
  • 53 Asia Pacifc Pancreatic Cancer Market Outlook, By Chemotherapy (2016-2026) (US $MN)
  • 54 Asia Pacifc Pancreatic Cancer Market Outlook, By Targeted Therapy (2016-2026) (US $MN)
  • 55 Asia Pacifc Pancreatic Cancer Market Outlook, By Surgery (2016-2026) (US $MN)
  • 56 Asia Pacifc Pancreatic Cancer Market Outlook, By Radiation Therapy (2016-2026) (US $MN)
  • 57 Asia Pacifc Pancreatic Cancer Market Outlook, By Other Treatments (2016-2026) (US $MN)
  • 58 Asia Pacifc Pancreatic Cancer Market Outlook, By Type (2016-2026) (US $MN)
  • 59 Asia Pacifc Pancreatic Cancer Market Outlook, By Exocrine Pancreas Cancer (2016-2026) (US $MN)
  • 60 Asia Pacifc Pancreatic Cancer Market Outlook, By Endocrine Pancreas Cancer (2016-2026) (US $MN)
  • 61 Asia Pacifc Pancreatic Cancer Market Outlook, By End User (2016-2026) (US $MN)
  • 62 Asia Pacifc Pancreatic Cancer Market Outlook, By Research Institute (2016-2026) (US $MN)
  • 63 Asia Pacifc Pancreatic Cancer Market Outlook, By Hospitals & Clinics (2016-2026) (US $MN)
  • 64 Asia Pacifc Pancreatic Cancer Market Outlook, By Other End Users (2016-2026) (US $MN)
  • 65 South America Pancreatic Cancer Market Outlook, By Country (2016-2026) (US $MN)
  • 66 South America Pancreatic Cancer Market Outlook, By Treatment (2016-2026) (US $MN)
  • 67 South America Pancreatic Cancer Market Outlook, By Biologic Therapy (2016-2026) (US $MN)
  • 68 South America Pancreatic Cancer Market Outlook, By Hormone Therapy (2016-2026) (US $MN)
  • 69 South America Pancreatic Cancer Market Outlook, By Chemotherapy (2016-2026) (US $MN)
  • 70 South America Pancreatic Cancer Market Outlook, By Targeted Therapy (2016-2026) (US $MN)
  • 71 South America Pancreatic Cancer Market Outlook, By Surgery (2016-2026) (US $MN)
  • 72 South America Pancreatic Cancer Market Outlook, By Radiation Therapy (2016-2026) (US $MN)
  • 73 South America Pancreatic Cancer Market Outlook, By Other Treatments (2016-2026) (US $MN)
  • 74 South America Pancreatic Cancer Market Outlook, By Type (2016-2026) (US $MN)
  • 75 South America Pancreatic Cancer Market Outlook, By Exocrine Pancreas Cancer (2016-2026) (US $MN)
  • 76 South America Pancreatic Cancer Market Outlook, By Endocrine Pancreas Cancer (2016-2026) (US $MN)
  • 77 South America Pancreatic Cancer Market Outlook, By End User (2016-2026) (US $MN)
  • 78 South America Pancreatic Cancer Market Outlook, By Research Institute (2016-2026) (US $MN)
  • 79 South America Pancreatic Cancer Market Outlook, By Hospitals & Clinics (2016-2026) (US $MN)
  • 80 South America Pancreatic Cancer Market Outlook, By Other End Users (2016-2026) (US $MN)
  • 81 Middle East & Africa Pancreatic Cancer Market Outlook, By Country (2016-2026) (US $MN)
  • 82 Middle East & Africa Pancreatic Cancer Market Outlook, By Treatment (2016-2026) (US $MN)
  • 83 Middle East & Africa Pancreatic Cancer Market Outlook, By Biologic Therapy (2016-2026) (US $MN)
  • 84 Middle East & Africa Pancreatic Cancer Market Outlook, By Hormone Therapy (2016-2026) (US $MN)
  • 85 Middle East & Africa Pancreatic Cancer Market Outlook, By Chemotherapy (2016-2026) (US $MN)
  • 86 Middle East & Africa Pancreatic Cancer Market Outlook, By Targeted Therapy (2016-2026) (US $MN)
  • 87 Middle East & Africa Pancreatic Cancer Market Outlook, By Surgery (2016-2026) (US $MN)
  • 88 Middle East & Africa Pancreatic Cancer Market Outlook, By Radiation Therapy (2016-2026) (US $MN)
  • 89 Middle East & Africa Pancreatic Cancer Market Outlook, By Other Treatments (2016-2026) (US $MN)
  • 90 Middle East & Africa Pancreatic Cancer Market Outlook, By Type (2016-2026) (US $MN)
  • 91 Middle East & Africa Pancreatic Cancer Market Outlook, By Exocrine Pancreas Cancer (2016-2026) (US $MN)
  • 92 Middle East & Africa Pancreatic Cancer Market Outlook, By Endocrine Pancreas Cancer (2016-2026) (US $MN)
  • 93 Middle East & Africa Pancreatic Cancer Market Outlook, By End User (2016-2026) (US $MN)
  • 94 Middle East & Africa Pancreatic Cancer Market Outlook, By Research Institute (2016-2026) (US $MN)
  • 95 Middle East & Africa Pancreatic Cancer Market Outlook, By Hospitals & Clinics (2016-2026) (US $MN)
  • 96 Middle East & Africa Pancreatic Cancer Market Outlook, By Other End Users (2016-2026) (US $MN)
Back to Top